India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
The Uttarakhand Tourism Development Board has teamed up with Starscapes, an astro-tourism company, to introduce…
In a gesture of solidarity and recognition, Palestinian journalists covering the crisis in Gaza have…
Retired Justice Sanjaya Kumar Mishra has been appointed as the President of the Goods &…
Atanu Chakraborty's re-appointment as part-time Chairman of HDFC Bank for three years, effective from May…
American Express is set to inaugurate its expansive new campus in Gurugram, spanning nearly one…
In the latest edition of the World Press Freedom Index published annually by Reporters Without…